Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

137 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego
PR
Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego
PR
Lilly to Participate in Evercore ISI HealthCONx Conference
PR
Eli Lilly and Company Announces Executive Changes
CI
Eli Lilly Diabetes, Obesity Head Mike Mason to Retire
DJ
Lilly Announces Leadership Transitions
PR
Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference
PR
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
PR
ELI LILLY & CO : Change in Directors or Principal Officers (form 8-K)
AQ
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
PR
Lilly to Participate in Citi's 17th Annual BioPharma Conference
PR
Lilly to Participate in Bank of America Securities 2022 Healthcare Conference
PR
Eli Lilly obesity drug data shines, shares rise
RE
Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
PR
Eli Lilly pushes back timeline for Alzheimer's drug application
RE
Eli Lilly and : Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting - Form 8-K
PU
Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting
PR
Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference
PR
Eli Lilly Gets Expanded FDA EUA for Covid-19 Treatment for Some High-Risk Individuals
DJ
Regeneron Pharmaceuticals : U.S. buys additional doses of Eli Lilly, Regeneron COVID-19 therapy
RE
Eli Lilly bets on Alzheimer's disease drug data as it chases Biogen
RE
Eli Lilly and : Lilly to Participate in Guggenheim Biopharma Strategy Series
PR
MYRIAD GENETICS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Transcript : Myriad Genetics, Inc. - Shareholder/Analyst Call
Eli Lilly and : Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
AQ
Lilly Ends U.S. Use of Single Covid-19 Antibody Drug Alone -- Update
DJ
New Covid-19 Strains Prompt Lilly to Seek to End U.S. Use of Single Antibody Drug Alone
DJ
Eli Lilly and : Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
AQ
Myriad Genetics : Annual Transition Report (SEC Filing - 10-KT)
PU
Lilly Alzheimer's drug shows benefit on cognition, function in mid-stage trial
RE
Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM
PR
Eli Lilly's combo therapy for COVID-19 cuts serious illness and death in large study
RE
Eli Lilly and Company : - Lilly to Participate in Cowen Health Care Conference
AQ
Eli Lilly and : Lilly to Participate in Cowen Health Care Conference
PR
Eli Lilly and : Lilly's bamlanivimab administered with etesevimab receives FDA emergency use authorization for COVID-19
AQ
Eli Lilly and : Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab with VIR-7831 for COVID-19
AQ
Eli Lilly and Company : - New data show treatment with Lilly's neutralizing antibodies bamlanivimab and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent
AQ
GlaxoSmithKline : Eli Lilly, Vir Partner on Therapy for Moderate Covid-19 Cases
DJ
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
GL
Eli Lilly and Company : - Lilly's neutralizing antibody bamlanivimab prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
AQ
Eli Lilly and : Lilly Antibody Drug Prevents Covid-19 in Nursing Homes, Study Finds
DJ
Eli Lilly and : Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
PR
Eli Lilly and Company : - Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial
AQ
Regeneron Pharmaceuticals : says antibodies likely potent vs virus variants, Lilly concerned about S. Africa version
RE
Eisai : Lilly Alzheimer's drug slows mental, functional decline in mid-stage trial, shares jump
RE
Eli Lilly and : Lilly Alzheimer's Drug Helped Patients in Small Trial -- Update
DJ
Eli Lilly and : Lilly Alzheimer's Drug Helped Patients in Small Trial
DJ
Eli Lilly and : Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial
PR
Eisai : Lilly says Alzheimer's drug slows clinical decline in mid-stage trial
RE
Eli Lilly and : Highly Touted Monoclonal Antibody Therapies Sit Unused in Hospitals
DJ
No results for this search
  1. Stock Market
  2. Advanced search
  3. Daniel Skovronsky
  4. News